natgillin/translations-raw huggingface dataset:
For practical information about using Tolucombi, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Tolucombi naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
What is Tolucombi and what is it used for?
Kaj je zdravilo Tolucombi in za kaj se uporablja?
The dose of Tolucombi to be used depends on the dose of telmisartan that the patient was taking before: patients who were receiving 40 mg telmisartan should take the 40/12.5 mg tablets, and patients who were receiving 80 mg telmisartan should take the 80/12.5 mg tablets.
Odmerek zdravila Tolucombi je odvisen od odmerka telmisartana, ki ga je bolnik jemal pred tem: bolniki, ki so prejemali 40 mg telmisartana, morajo jemati tablete po 40/12,5 mg, tisti, ki pa so prejemali 80 mg telmisartana, pa morajo jemati tablete po 80/12,5 mg. Tablete po 80/25 mg se dajejo bolnikom, pri katerih se krvni tlak ne uravna z jemanjem tablet po 80/12,5 mg ali pri katerih se je krvni tlak stabiliziral z uporabo dveh zdravilnih učinkovin, ki so ju jemali ločeno, preden so prešli na zdravilo Tolucombi.
Tolucombi is a medicine that contains two active substances, telmisartan and hydrochlorothiazide.
Tolucombi je zdravilo, ki vsebuje dve zdravilni učinkovini, telmisartan in hidroklorotiazid.
Why is Tolucombi approved?
Zakaj je bilo zdravilo Tolucombi odobreno?
Tolucombi contains two active substances, telmisartan and hydrochlorothiazide.
Zdravilo Tolucombi vsebuje dve zdravilni učinkovini, telmisartan in hidroklorotiazid.
It is not intended to provide practical advice on how to use Tolucombi.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
How has Tolucombi been studied?
Kako je bilo zdravilo Tolucombi raziskano?
How does Tolucombi work?
Kako zdravilo Tolucombi deluje?
How is Tolucombi used?
Kako se zdravilo Tolucombi uporablja?
4.8 Undesirable effects a.Summary of the safety profile
4.8 Neželeni učinki a. Povzetek varnostnega profila
Tell your doctor or pharmacist if you are using have recently used or might use any other medicines.
Obvestite zdravnika ali farmacevta, če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo.
The needle safety guard will rapidly move to cover the needle (see picture 7).
Varnostni pripomoček se bo hitro premaknil, da bo pokril iglo (glejte sliko 7).
- osteoporosis (bone disease).
- osteoporozo (bolezen kosti).
Date of first authorisation: 15 September 2008.
Datum prve odobritve: 15. september 2008 Datum zadnjega podaljšanja: 19. julij 2013
Congenital, idiopathic or cyclic neutropenia:
Prirojena, idiopatska ali ciklična nevtropenija:
Do not warm Tevagrastim in any other way (for example, do not warm it in a microwave or in hot water).
Zdravila Tevagrastim ne smete segrevati na kak drug način (na primer v mikrovalovni pečici ali v vroči vodi).
Your doctor may want to monitor you closely , see section 4 of the package leaflet.
Zdravnik vas bo morda želel pozorno spremljati, glejte poglavje 4 v teh navodilih za uporabo.
Do not release the pressure on the plunger!
Ne popustite pritiska na bat!
Before you inject Tevagrastim you must do the following:
Pred injiciranjem zdravila Tevagrastim morate narediti naslednje:
Push the plunger up to the number (mL) on the syringe that matches the dose of Tevagrastim that your doctor prescribed.
Bat potisnite navzgor do številke (ml), ki se sklada z odmerkom zdravila Tevagrastim, ki vam ga je predpisal vaš zdravnik.
When diluted in glucose 50 mg/mL (5 %) solution for infusion, Tevagrastim is compatible with glass and a variety of plastics including PVC, polyolefin (a co-polymer of polypropylene and polyethylene) and polypropylene.
Če je razredčeno v raztopini glukoze 50 mg/ml (5 %) za infundiranje, je zdravilo Tevagrastim kompatibilno s steklom in vrsto plastičnih snovi, med katerimi so PVC, poliolefin (kopolimer polipropilena in polietilena) in polipropilen.
If you develop or are likely to develop cancers of the blood, you should not use Tevagrastim, unless instructed by your doctor.
Če se pri vas razvije krvni rak ali je verjetno, da se bo, zdravila Tevagrastim ne smete uporabljati, razen če vam tega ne naroči vaš zdravnik.
Following established chemotherapy for solid tumours, lymphomas and lymphoid leukaemias, it is expected that the duration of treatment required to fulfil these criteria will be up to 14 days.
Po uveljavljeni kemoterapiji za čvrste tumorje, limfome in pri limfoidini levkemiji se pričakuje, da bo trajanje zdravljenja, če želimo doseči zahtevane kriterije, do 14 dni.
b. Tabulated summary of adverse reactions
b. Tabelarični povzetek neželenih učinkov
Tevagrastim contains sorbitol (E420).
Zdravilo Tevagrastim vsebuje sorbitol (E420).
If you are a patient with severe chronic neutropenia, you may be at risk of developing cancer of the blood (leukaemia, myelodysplastic syndrome [MDS]).
Če ste bolnik s hudo kronično nevtropenijo, lahko pri vas obstaja tveganje za nastanek krvnega raka (levkemija, mielodisplastični sindrom (MDS - myelodisplastic syndrome)).
Randomised, single-blind, single dose, crossover studies in 196 healthy volunteers showed that the pharmacokinetic profile of Tevagrastim was comparable to that of the reference product after subcutaneous and intravenous administration.
Randomizirane, enojno slepe navzkrižne študije z enkratnim odmerkom pri 196 zdravih prostovoljcih so pokazale, da je farmakokinetičen profil zdravila Tevagrastim primerljiv s profilom referenčnega zdravila po subkutanem in intravenskem apliciranju.
The results of flow cytometric analysis of CD34+ cell numbers vary depending on the precise methodology used and recommendations of numbers based on studies in other laboratories need to be interpreted with caution.
Rezultati meritev števila celic CD34+ s pretočno citometrijo se med seboj razlikujejo glede na dejansko uporabljeno metodologijo, zato je treba priporočila o številu celic, ki temeljijo na študijah v drugih laboratorijih, interpretirati previdno.
How long will I have to take Tevagrastim?
Koliko časa bom moral jemati zdravilo Tevagrastim?
Check again to make sure the correct dose of Tevagrastim is in the syringe.
Še enkrat preverite, če je v brizgi ustrezen odmerek zdravila Tevagrastim.
The efficacy and safety of Tevagrastim has been assessed in randomised, controlled phase III studies in breast cancer, lung cancer and Non-Hodgkin-Lymphoma.
Učinkovitost in varnost zdravila Tevagrastim sta bili ocenjeni v randomiziranih in nadzorovanih študijah faze III pri bolnikih z rakom dojk, rakom na pljučih in Ne-Hodkinovim limfomom.
if you are being treated for severe chronic neutropenia and you have blood in your urine (haematuria).
- če vas zdravijo zaradi hude kronične nevtropenije in imate kri v urinu (hematurija).
This section contains information on how to give yourself an injection of Tevagrastim.
To poglavje vsebuje podatke o tem, kako si sami injicirate zdravilo Tevagrastim.
Timing of leukapheresis: 1 or 2 leukapheresis on days 5 and 6 are often sufficient.
Časovna razporeditev levkaferez: običajno zadostujeta 1 do 2 levkafrezi 5. in 6. dan.
What should I do before I give myself a subcutaneous injection of Tevagrastim?
Kaj moram narediti, preden si dam subkutano injekcijo zdravila Tevagrastim?
Tevagrastim is a white blood cell growth factor (granulocyte colony stimulating factor) and belong to a group of medicines called cytokines.
Zdravilo Tevagrastim je rastni faktor za bele krvničke (granulocitne kolonije stimulirajoči faktor) in spada v skupino zdravil, imenovanih citokini.
Assessment of progenitor cell yields
Ocena donosa matičnih celic
You will need to take Tevagrastim until your white blood cell count is normal.
Zdravilo Tevagrastim boste morali jemati, dokler ne bo število belih krvničk v vaši krvi normalno.
Nevertheless, a risk of promotion of a malignant myeloid clone can not be excluded.
Tveganja za napredovanje mieloidnega rakastega klona ni možno izključiti.
If you use more Tevagrastim than you should, contact your doctor or pharmacist as soon as possible.
Če ste uporabili večji odmerek zdravila Tevagrastim, kot bi smeli, se čimprej posvetujte z zdravnikom ali farmacevtom.
To give yourself a subcutaneous injection you will need: - a pre-filled syringe of Tevagrastim; - alcohol wipes or similar.
Za subkutano samoinjiciranje boste potrebovali: - napolnjeno injekcijsko brizgo z zdravilom Tevagrastim, - alkoholne krpice ali podobno,
Tevagrastim is usually given as a daily injection into the tissue just under the skin (known as a subcutaneous injection).
Zdravilo Tevagrastim običajno dajemo vsakodnevno v obliki injekcije v tkivo tik pod kožo (temu pravimo subkutana injekcija).
There were no relevant differences between Tevagrastim and the reference product with regard to duration of severe neutropenia and incidence of febrile neutropenia.
Med zdravilom Tevagrastim in referenčnim zdravilom ni bilo očitne razlike v zvezi s trajanjem hude nevtropenije in nastanka febrilne nevtropenije.
Take your Tevagrastim pre-filled syringe out of the refrigerator.
Vzemite napolnjeno injekcijsko brizgo z zdravilom Tevagrastim iz hladilnika.
In randomised clinical trials, a subcutaneous dose of 23 MIU (230 μg)/m2/day (4.0 to 8.4 μg/kg/day) was used.
V randomiziranih kliničnih preskušanjih so uporabljali subkutani odmerek 23 milijonov i.e. (230 μg)/m2/dan (4,0 do 8,4 μg/kg/dan).
Disinfect the injection site by using an alcohol wipe and pinch the skin between your thumb and forefinger, without squeezing it (see picture 5).
Razkužite mesto injiciranja z alkoholno krpico in primite kožo s palcem in kazalcem, ne da bi jo stiskali (glejte sliko 5).
A subset of approximately 12 % of patients who had normal cytogenetic evaluations at baseline was subsequently found to have abnormalities, including monosomy 7, on routine repeat evaluation.
Pri podskupini približno 12 % bolnikov, ki so imeli na začetku normalen citogenetski izvid, so pri poznejšem ponovnem rutinskem pregledu ugotovili nepravilnosti, vključno z monosomijo 7.
Because of the potential of receiving higher doses of chemotherapy (e.g., full doses on the prescribed schedule) the patient may be at greater risk of thrombocytopenia and anaemia.
Zaradi možnosti prejemanja večjih odmerkov kemoterapije (npr. polnih odmerkov po predpisani shemi), je lahko bolnik bolj ogrožen zaradi trombocitopenije in anemije.
White blood cell counts of 100 x 109/L or greater have been observed in less than 5 % of patients receiving filgrastim at doses above 0.3 MIU/kg/day (3 μg/kg/day).
Število belih krvničk 100 x 109/l ali več so ugotovili pri manj kot 5 % bolnikov z rakom, ki so prejemali filgrastim v odmerkih, večjih od 0,3 M i.e./kg/dan (3 μg/kg/dan).
Other medicines and Tevagrastim
Druga zdravila in zdravilo Tevagrastim
Tevagrastim is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
Zdravilo Tevagrastim se uporablja za zdravljenje dolgotrajne nevtropenije (ANC manjše ali enako 1,0 x 109/l) pri bolnikih z napredovalo okužbo HIV, z namenom zmanjšanja tveganja bakterijskih okužb, ko druge oblike zdravljenja nevtropenije niso primerne.
If you forget to use Tevagrastim
Če ste pozabili uporabiti zdravilo Tevagrastim
Contents of the pack and other information What Tevagrastim contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Tevagrastim
Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (≥ 20 µg/kg/day) and slightly reduced survival rate (100 µg/kg/day).
Pri potomcih podgan, ki so jim dali filgrastim v času poroda ali obdobju laktacije, so opazili zamudo v zunanji diferenciaciji in zastoj rasti (≥ 20 µg/kg/dan) in nekoliko zmanjšano stopnjo preživetja
Pre-filled syringe (type I glass) with injection needle (stainless steel), with or without a needle safety guard.
Napolnjena injekcijska brizga (steklo tipa I) z injekcijsko iglo (iz nerjavečega jekla), z varnostno zaščito za iglo ali brez nje.
A common side effect of Tevagrastim use is pain in your muscles or bones (musculoskeletal pain), which could be relieved by taking standard pain relief medicines (analgesics).
Pogost neželeni učinek uporabe zdravila Tevagrastim so bolečine v mišicah in kosteh (mišičnoskeletne bolečine), ki jih je mogoče lajšati s standardnimi protibolečinskimi zdravili (analgetiki).
Using the pre-filled syringe without a needle safety guard Administer the dose as per standard protocol.
Uporaba napolnjene injekcijske brizge brez varnostne zaščite za iglo Odmerek aplicirajte po standardnem protokolu.
Tevagrastim is a solution for injection/infusion in a pre-filled syringe.
Zdravilo Tevagrastim je raztopina za injiciranje/infundiranje v napolnjeni injekcijski brizgi.
In view of the possible risk of microbial contamination, Tevagrastim syringes are for single use only.
Ker obstaja tveganje mikrobne kontaminacije so z zdravilom Tevagrastim napolnjene brizge namenjene izključno enkratni uporabi.
One retrospective European study evaluating the use of G-CSF after allogeneic bone marrow transplantation in patients with acute leukaemias suggested an increase in the risk of GvHD, treatment related mortality (TRM) and mortality when G-CSF was administered.
Ena retrospektivna evropska študija, v kateri so ocenili uporabo G-CSF po alogenski presaditvi kostnega mozga pri bolnikih z akutno levkemijo, je pokazala zvišanje tveganja za GvHD, z zdravljenjem povezano smrtnostjo (treatment related mortality - TRM) in smrtnost pri uporabi
In a separate retrospective international study in patients with acute and chronic myelogenous leukaemias, no effect on the risk of GvHD, TRM and mortality was seen.
V drugi retrospektivna mednarodna študija pri bolnikih z akutnimi in kroničnimi mielogenimi levkemijami niso opazili tveganja za GvHD, TRM in smrtnost.
While maintaining pressure on the plunger, remove the syringe from the patient.
Medtem ko še vedno vzdržujete pritisk na bat, odstranite iglo iz bolnika.
Based on reported data for another filgrastim product similar to the reference product, comparable findings plus increased foetal malformations were observed at 100 µg/kg/day, a maternally toxic dose which corresponded to a systemic exposure of approximately 50-90 times the exposures observed in patients treated with the clinical dose of 5 µg/kg/day.
Na osnovi podatkov za drugo zdravilo, ki vsebuje filgrastim in je podobno referenčnem zdravilu, so primerljive ugotovitve ter zvečano število malformacij ploda opazili pri 100 µg/kg/dan, pri odmerku, ki je bil toksičen za mater in ustreza približno 50-90-krat večji sistemski izpostavljenosti kot je izpostavljenost bolnikov, ki se zdravijo s kliničnimi odmerki 5 μg/kg/dan.
Special caution should be used when treating patients with high dose chemotherapy because improved tumour outcome has not been demonstrated and intensified doses of chemotherapeutic agents may lead to increased toxicities including cardiac, pulmonary, neurologic and dermatologic effects (please refer to the Summary of Product Characteristics of the specific chemotherapy agents used).
Posebna previdnost je potrebna tudi pri zdravljenju bolnikov, ki prejemajo kemoterapijo v velikih odmerkih, ker ni bil dokazan boljši izid, kar zadeva tumorje in lahko večji odmerki kemoterapevtikov vodijo do povečane toksičnosti, vključno s srčnimi, pljučnimi, nevrološkimi in dermatološkimi učinki (glejte povzetek glavnih značilnosti zdravila za posamezne uporabljene kemoterapevtike).
Causes of transient neutropenia such as viral infections should be excluded.
Drugi posebni previdnostni ukrepi Izključiti je treba vzroke prehodne nevtropenije, na primer virusno okužbo.
Tevagrastim is indicated for the mobilisation of peripheral blood progenitor cells (PBPC).
Zdravilo Tevagrastim se uporablja za izplavljanje krvotvornih matičnih celic v periferno kri (peripheral blood progenitor cells - PBPC).
Unless your doctor directs you otherwise, you must stop breast-feeding if you use Tevagrastim
Razen če vam zdravnik ne naroči drugače, morate med uporabo zdravila Tevagrastim prenehati z dojenjem.
Filgrastim acts primarily on neutrophil precursors to exert its effect in elevating neutrophil counts.
Filgrastim deluje v glavnem na prekurzorje za nevtrofilce, kar vpliva na povišanje števila nevtrofilcev.
If you use more Tevagrastim than you should
Če ste uporabili večji odmerek zdravila Tevagrastim, kot bi smeli
The most suitable places to inject yourself are: - the top of your thighs; and - the abdomen, except for the area around the navel (see picture 3).
- zgornji del stegen; in - trebuh, razen predela okrog popka (glejte sliko 3).
Your doctor will tell you how much Tevagrastim you should take.
Zdravnik vam bo povedal, koliko zdravila Tevagrastim morate vzeti.
In cancer patients, the pharmacokinetic profile of Tevagrastim and the reference product was comparable after single and repeated subcutaneous administration.
Pri bolnikih z rakom sta bila farmakokinetična profila zdravila Tevagrastim in referenčnega zdravila primerljiva po enkratnem in ponavljajočem odmerku, ki so ga bolniki prejeli po subkutani poti.
- if you have any of the following or combination of the following side effects: swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness.
- če se vam pojavi kateri od naslednjih neželenih učinkov ali kombinacija teh neželenih učinkov: oteklost ali zabuhlost, ki jo lahko spremlja manj pogostejše odvajanje urina, težko dihanje, oteklost trebuha in občutek polnosti ter splošen občutek utrujenosti.
Tevagrastim is used to treat children who are receiving chemotherapy or who suffer from severe low white blood cell count (neutropenia).
Zdravilo Tevagrastim uporabljamo za zdravljenje otrok, ki prejemajo kemoterapijo ali ki imajo močno zmanjšano število belih krvničk (nevtropenija).
Tevagrastim is a biosimilar medicinal product.
Tevagrastim je biološko podobno zdravilo.
Accidental exposure to freezing temperatures does not adversely affect the stability of Tevagrastim.
Če je zdravilo Tevagrastim pomotoma izpostavljeno temperaturam pod lediščem, to ne škoduje njegovi stabilnosti.
If you become pregnant during Tevagrastim treatment, please inform your doctor.
Če med zdravljenjem z zdravilom Tevagrastim zanosite, o tem obvestite svojega zdravnika.
If required, Tevagrastim may be diluted in glucose 50 mg/mL (5 %) solution for infusion.
Če je potrebno, lahko zdravilo Tevagrastim razredčite v raztopini glukoze 50 mg/ml (5 %) za infundiranje.
Tevagrastim containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.
Zdravilo Tevagrastim, ki vsebuje rekombinantni človeški G-CSF (filgrastim) v 24-ih urah povzroči izrazito zvišanje števila nevtrofilcev v periferni krvi, medtem ko je zvišanje monocitov manjše.
Tevagrastim 48 MIU/0.8 mL
Tevagrastim 48 M i.e./0,8 ml
How is Tevagrastim given and much should I take?
Kako se daje zdravilo Tevagrastim in koliko ga moram vzeti?
ANC should be monitored closely, especially during the first few weeks of filgrastim therapy.
Skrbno je treba spremljati absolutno število nevtrofilcev (ANC), še posebej v prvih nekaj tednih zdravljenja s filgrastimom.
Dispose of the syringe as instructed by your doctor, nurse or pharmacist.
Brizgo zavrzite, kot vam je naročil zdravnik, medicinska sestra ali farmacevt.
Your doctor will tell you how long you will need to take Tevagrastim.
Zdravnik vam bo povedal, koliko časa morate jemati zdravilo Tevagrastim.
There have been reports of graft versus host disease (GvHD) and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see section 4.8 and 5.1).
Obstajajo poročila o reakciji presadka proti gostitelju (»graft versus host disease« - GvHD) in o smrtnih primerih pri bolnikih, ki so prejemali G-CSF po alogenski presaditvi kostnega mozga (glejte poglavji 4.8 in 5.1).
- if you have a combination of any of the following symptoms: fever, or shivering, or feeling very cold, high heart rate, confusion or disorientation, shortness of breath, extreme pain or discomfort and clammy or sweaty skin.
- če se vam pojavi kombinacija katerihkoli izmed naslednjih neželenih učinkov: vročina ali drhtenje ali hudo mrazenje, hiter srčni utrip, zmedenost ali dezorientiranost, kratka sapa, izjemna bolečina ali nelagodje ter lepljiva ali znojna koža.
Patients who have undergone very extensive prior myelosuppressive therapy may not show sufficient mobilisation of PBPC to achieve the recommended minimum yield (≥ 2.0 x 106 CD34+ cells/kg) or acceleration of platelet recovery to the same degree.
Predhodna izpostavljenost citotoksičnim zdravilom Pri bolnikih, ki so imeli zelo obsežno predhodno mielosupresivno zdravljenje, morda ne bo prišlo do zadostnega izplavljanja krvotvornih matičnih celic v periferno kri, da bi dosegli najmanjši priporočeni delež celic (≥ 2,0 milijona CD34+ celic/kg) oziroma pospešili povečevanje števila trombocitov v enaki meri.
Tevagrastim is a clear and colourless solution.
Zdravilo Tevagrastim je bistra in brezbarvna raztopina.
In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Tevagrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
Bolnikom, otrokom ali odraslim s hujšo obliko kongenitalne, ciklične ali idiopatične nevtropenije z absolutnim številom nevtrofilcev (ANC) ≤ 0,5 x 109/l in s hujšimi ali ponavljajočimi se okužbami, se dolgotrajno jemanje zdravila Tevagrastim predpiše zato, da se poveča število nevtrofilcev in zmanjša pogostost nastanka in trajanja z okužbami povezanih pojavov.
Tevagrastim does not contain any preservative.
Zdravilo Tevagrastim ne vsebuje konzervansov.
What Tevagrastim is and what it is used for What Tevagrastim is
Kaj je zdravilo Tevagrastim in za kaj ga uporabljamo Kaj je zdravilo Tevagrastim
How do I prepare my Tevagrastim injection?
Kako si pripravim z zdravilom Tevagrastim napolnjeno injekcijo?
What Tevagrastim looks like and contents of the pack
Izgled zdravila Tevagrastim in vsebina pakiranja
The degree of variation between individual patients and between laboratory assays of CD34+ cells mean that direct comparison between different studies is difficult.
CD34+ celic pomeni, da je neposredna primerjava med različnima študijama težavna.
Tevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
Zdravilo Tevagrastim je indicirano za skrajšanje trajanja nevtropenije in v primeru nastanka febrilne nevtropenije pri bolnikih, ki prejemajo citotoksično kemoterapijo za maligne tvorbe (z izjemo kronične mieloične levkemije in mielodisplastičnih sindromov), ter za skrajšanje trajanja nevtropenije pri bolnikih, ki se zdravijo z mieloablativno terapijo po presaditvi kostnega mozga, pri katerih obstaja povečano tveganje za dlje trajajočo hudo nevtropenijo.
Find a comfortable, well-lit place and put everything you need where you can reach them (the Tevagrastim pre-filled syringe and alcohol wipes).
Poiščite si udoben, dobro osvetljen prostor in si pripravite vse, kar boste potrebovali, tako da bo pri roki (z zdravilom Tevagrastim napolnjeno injekcijsko brizgo in alkoholne krpice)
The effects of filgrastim in patients with substantially reduced myeloid progenitors have not been studied.
Drugi posebni previdnostni ukrepi Učinki filgrastima na bolnike z znatno zmanjšanim številom matičnih celic mieloične vrste niso bili raziskani.